Also see: EMC, Jazz Pharma: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Amerigroup ( AGP) estimates, target cut at Oppenheimer. AGP estimates were reduced through 2012. Company continues to face higher costs. Outperform rating and new $69 price target.

Ametek ( AME - Get Report) estimates higher at UBS. AME estimates increased through 2012, UBS said. Raising sales outlook, nudging margin estimates up. Maintain $47 price target and Neutral rating.

Amgen ( AMGN - Get Report) estimates lowered at Oppenheimer through 2012. Company is seeing higher Neulasta and Enbrel sales. Outperform rating and $66 price target.

Amgen ( AMGN - Get Report) estimates, target raised at UBS. Shares of AMGN now seen reaching $58. Estimates also increased on pricing power in the base business. Neutral rating.

Apollo ( APOL) added to Conviction Buy List at Goldman. $62 price target. Company should see better enrollment growth.

Arrow Electronics ( ARW) numbers lowered at Credit Suisse. Shares of ARW now seen reaching $39. Estimates also cut, as demand remains soft. Neutral rating.

Borg Warner ( BWA) estimates, target raised at Citigroup. Shares of BWA now seen reaching $88. Estimates also raised on stronger top line performance and better conversion. Hold rating.

CB Richard Ellis ( CBG) estimates, target lowered at Barclays. Shares of CBG now seen reaching $30. Estimates also lowered on lower terminal growth rate. Overweight rating.

Colgate-Palmolive ( CL - Get Report) estimates lowered at UBS through 2012. Underlying fundamentals weaker and ability to forecast is deteriorating. Maintain $84 price target and Neutral rating.

Coventry Health ( CVH) numbers increased at Barclays. CVH estimates were raised through 2012. Company boosted its guidance. Equal-weight rating and new $38 price target.

Chevron ( CVX - Get Report) estimates, target increased at Barclays. Shares of CVX now seen reaching $135, according to Barclays. Estimates also raised on higher oil price leverage and relative valuation. Overweight rating.

EQT Corporation ( EQT) estimates, target increased at Barclays. Shares of EQT now seen reaching $77, Barclays said. Estimates also increased on potential change to corporate structure. Overweight rating.

Federated Investors ( FII) estimates, target reduced at Barclays. Shares of FII now seen reaching $24. Estimates also lowered on increased net fee waivers. Equal Weight rating.

Helmerich & Payne ( HP) numbers raised at Goldman. Shares of HP now seen reaching $80. Estimates also increased, as the company is executing on its newbuild strategy. Neutral rating.

Helmerich & Payne estimates, target raised at UBS. Shares of HP now seen reaching $75. Estimates also raised to reflect additional newbuilds. Neutral rating.

ITT ( ITT) estimates, target reduced at Goldman. ITT estimates were lowered through 2013. Company is realizing lower defense margins. Neutral rating and new $64 price target.

LyondellBasell ( LYB) estimates increased at UBS through 2011. Strong Q2 beat. Maintain $47 price target and Buy rating.

Marriott ( MAR) estimates, target reduced at Jefferies. MAR estimates were cut through 2012, Jefferies said. Company is facing multiple growth headwinds. Buy rating.

Newell Rubbermaid ( NWL) numbers lowered at Morgan Stanley. Shares of NWL now seen reaching $20. Estimates also cut, as the company is generating less cash flow. Overweight rating.

Owens-Illinois ( OI) numbers cut at Goldman. Shares of OI now seen reaching $28. Estimates also lowered, given the company's lower volume guidance. Neutral rating.

Priceline.com ( PCLN) numbers raised at ThinkEquity. Shares of PCLN now seen reaching $725. Estimates also increased, as the company should continue to deliver solid growth. Buy rating.

Sally Beauty ( SBH) numbers upped at Credit Suisse. SBH estimates were boosted through 2013. Company is seeing higher sales growth. Outperform rating and new $19 price target.

Southwestern Energy ( SWN) numbers increased at Morgan Stanley. SWN estimates were raised through 2013, Morgan Stanley said. Company is realizing higher oil production. Neutral rating and new $51 price target.

Torchmark ( TMK) estimates, target boosted at Credit Suisse. Shares of TMK now seen reaching $41. Estimates also upped, as the company is buying back more stock. Underperform rating.

Weyerhaeuser ( WY) estimates lowered at UBS.WY estimates decreased through 2012. More conservative outlook on the housing recovery. Maintain $18 price target and Sell rating.

End of report.

This article was written by a staff member of TheStreet.